Last reviewed · How we verify
HS235
At a glance
| Generic name | HS235 |
|---|---|
| Sponsor | 35Pharma Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects (PHASE1)
- A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults (PHASE1)
- Study of HS235 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS235 CI brief — competitive landscape report
- HS235 updates RSS · CI watch RSS
- 35Pharma Inc portfolio CI